Dyne Therapeutics officer to sell 5,658 shares
An officer of Dyne Therapeutics has filed a Rule 144 notice for broker-assisted sales of company common stock, including shares underlying equity compensation awards.
Rhea-AI Filing Summary
Dyne Therapeutics, Inc. (DYN) has a notice under Rule 144 for planned sales of common stock held for the account of officer John Cox. A broker, Stifel Nicolaus & Company Inc., is named to sell 5,658 shares of common stock with an aggregate market value of $106,844.00, based on 186,746,431 shares outstanding. The notice also identifies 9,081 shares underlying Restricted Stock Units from issuer equity compensation as securities to be sold, and it lists prior sales by Cox over the past three months.
Positive
- None.
Negative
- None.
Key Figures
Shares planned for sale: 5,658 shares
Aggregate market value of planned sale: $106,844.00
Shares outstanding: 186,746,431 shares
+3 more
6 metrics
Shares planned for sale
5,658 shares
Common stock to be sold through Stifel Nicolaus & Company Inc. under Rule 144
Aggregate market value of planned sale
$106,844.00
Market value of the 5,658 shares of common stock covered by the notice
Shares outstanding
186,746,431 shares
Common stock outstanding for Dyne Therapeutics, Inc. referenced in the Rule 144 notice
RSU-based shares to be sold
9,081 shares
Shares underlying Restricted Stock Units from issuer equity compensation
Prior sale on June 16, 2026
2,683 shares for $49,191.00
Common stock sold by John Cox during the past three months
Prior sale on August 13, 2026
4,986 shares for $131,034.00
Common stock sold by John Cox during the past three months
Key Terms
Rule 144, Restricted Stock Units, Equity Compensation, attorney-in-fact
4 terms
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Restricted Stock Units financial
"Common Stock | 09/04/2026 | Restricted Stock Units | Issuer"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Equity Compensation financial
"9081 | 09/04/2026 | Equity Compensation"
Equity compensation is pay given to employees, executives or contractors in the form of company ownership—such as stock, stock options or restricted shares—rather than just cash. It matters to investors because it can align workers' incentives with shareholders (like paying someone in slices of the same pie they help grow), but it also increases the number of shares outstanding and company expenses, affecting ownership percentages and earnings per share.
attorney-in-fact regulatory
"as a duly authorized representative of STIFEL, as attorney-in-fact for John Cox"
An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.
FAQ
What does the Form 144 filing indicate for Dyne Therapeutics (DYN)?
The Form 144 filing indicates that an officer, John Cox, has notified of intended sales of 5,658 shares of Dyne Therapeutics common stock through broker Stifel Nicolaus & Company Inc., and identified 9,081 RSU-based shares as additional securities to be sold under Rule 144.
What prior sales by John Cox in Dyne Therapeutics (DYN) stock are reported?
The filing reports that John Cox sold 2,683 shares for $49,191.00 on June 16, 2026, and 4,986 shares for $131,034.00 on August 13, 2026, in Dyne Therapeutics common stock during the past three months.
AI-generated analysis. How Rhea-AI works. Not financial advice.